Institute of Pharmacology and Toxicology, Technical University of Munich (TUM), Munich, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
J Clin Invest. 2022 Jun 1;132(11). doi: 10.1172/JCI159179.
The discovery of microRNAs and their role in diseases was a breakthrough that inspired research into microRNAs as drug targets. Cardiovascular diseases are an area in which limitations of conventional pharmacotherapy are highly apparent and where microRNA-based drugs have appreciably progressed into preclinical and clinical testing. In this Review, we summarize the current state of microRNAs as therapeutic targets in the cardiovascular system. We report recent advances in the identification and characterization of microRNAs, their manipulation and clinical translation, and discuss challenges and perspectives toward clinical application.
微小 RNA 的发现及其在疾病中的作用是一个突破，激发了人们将微小 RNA 作为药物靶点的研究。心血管疾病是传统药物治疗局限性非常明显的一个领域，基于微小 RNA 的药物已明显进入临床前和临床试验阶段。在这篇综述中，我们总结了微小 RNA 作为心血管系统治疗靶点的现状。我们报告了微小 RNA 的鉴定和特征、它们的操作和临床转化方面的最新进展，并讨论了向临床应用转化的挑战和前景。
